Search

Home > Diabetes Knowledge into Practice Podcast > Future approaches in T2D: technologies & targets | With Dr Alice Cheng
Podcast: Diabetes Knowledge into Practice Podcast
Episode:

Future approaches in T2D: technologies & targets | With Dr Alice Cheng
Category: Health
Duration: 00:11:11
Publish Date: 2021-11-02 05:00:00
Description:

In recent years there have been significant advances in the capabilities and availability of diabetes technologies. These are more widely used in type 1 diabetes, but could devices like continuous glucose monitors (CGMs) and closed-loop systems be useful for type 2 diabetes? What about time in range as a target? Join Dr Alice Cheng for a discussion of future uses of these technologies.

We’ve got a new website! Find it at diabetes.knowledgeintopractice.com, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter (@dkipractice) or connect on LinkedIn.


References:

American Diabetes Association. Diabetes Care. 2021;44(Supplement 1)

Boughton CK, et al. Fully automated closed-loop glucose control compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis: an open-label, randomized crossover trial. Nat Med. 2021 Aug;27(8):1471-1476. doi: 10.1038/s41591-021-01453-z. Epub 2021 Aug 4. Erratum in: Nat Med. 2021 Oct;27(10):1850.

Ajjan R, et al. The LIBERATES Trial - improving gLucose control in patIents with diaBEtes following myocaRdial infArction: The role of a novEl glycaemic monitoring Strategy. Presented at the 56th Annual Meeting of the European Association for the Study of Diabetes (EASD), 21 - 25 September 2020, virtual.


Disclosures: 

Dr Alice Cheng discloses the following: 

Advisory board member: Abbott, Astra Zenecea, Boehringher Ingelheim, Bayer, Dexcom, Eli Lilly, HLS Therapeutics, Insulet, Novo Nordisk, Sanofi, Takeda

Speaking honorarium: Abbott, Astra Zenecea, Boehringher Ingelheim, Bayer, Bausch,  Dexcom, Eli Lilly, HLS Therapeutics, Insulet, Janssen, Medtronic, Merck, Novo Nordisk, Sanofi

All conflicts of interest have been mitigated prior to this activity.

Target Audience

This educational activity is intended for an international audience of non-US and non-UK HCPs.

Funding

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.
Total Play: 0